77 related articles for article (PubMed ID: 2969133)
1. Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Hrushesky WJ; Von Roemeling R; Fraley EE; Rabatin JT
Semin Surg Oncol; 1988; 4(2):110-5. PubMed ID: 2969133
[TBL] [Abstract][Full Text] [Related]
2. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
[TBL] [Abstract][Full Text] [Related]
3. Circadian-based infusional FUDR therapy.
Lanning RM; von Roemeling R; Hrushesky WJ
Oncol Nurs Forum; 1990; 17(1):49-56. PubMed ID: 2137216
[TBL] [Abstract][Full Text] [Related]
4. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy].
Del Nero A; Mandressi A; Longo G; Cogni M; Mangiarotti B; Buzzetti V; Russo R
Arch Ital Urol Nefrol Androl; 1991 Jun; 63(2):249-51. PubMed ID: 1830673
[TBL] [Abstract][Full Text] [Related]
6. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.
von Roemeling R; Rabatin JT; Fraley EE; Hrushesky WJ
J Urol; 1988 Feb; 139(2):259-62. PubMed ID: 2963142
[TBL] [Abstract][Full Text] [Related]
7. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
[TBL] [Abstract][Full Text] [Related]
8. Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
Bjarnason GA; Doyle N; Sone M; Beattie K; Elia J; Owens B
J Infus Chemother; 1995; 5(2):82-8. PubMed ID: 8521240
[TBL] [Abstract][Full Text] [Related]
9. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Garufi C; Lévi F; Giunta S; Aschelter A; Pace R; Nisticò C; Terzoli E
J Infus Chemother; 1995; 5(3 Suppl 1):134-7. PubMed ID: 8528973
[TBL] [Abstract][Full Text] [Related]
10. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
12. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
von Roemeling R; Hrushesky WJ
J Clin Oncol; 1989 Nov; 7(11):1710-9. PubMed ID: 2530318
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
14. [Continuous sinusoid systemic Fudr infusion in advanced colorectal carcinoma. Preliminary experience].
Civalleri D; Cavallini M; Tirindelli Danesi D; Decian F; Depaoli M; Balletto N
Minerva Chir; 1992 May; 47(9):853-8. PubMed ID: 1535695
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
[TBL] [Abstract][Full Text] [Related]
17. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
19. [Neocarzinostatin therapy of advanced renal cell carcinoma].
Tari K; Satake I; Kojima S; Tsujii T; Yonese J
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2719-23. PubMed ID: 2970825
[TBL] [Abstract][Full Text] [Related]
20. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]